

REMARKS

The Applicants elect Group I: Claims 1-139 drawn to composition and method for treating neoplasms in a host employing an enhanced combination of a DNA topoisomerase I inhibitor and a cyclooxygenase-2 inhibitor, without traverse. Claims 140-181 are cancelled to more particularly point out the invention as embodied by Group I.

If the Examiner believes a telephonic interview with Applicant's representative would aid in the prosecution of this application, he is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

Date: 10/29/2002


James M. Warner
Attorney for Applicants
Reg. No. 45,199
314-694-3642 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
800 N. Lindbergh Blvd.
Mail Zone 04E
St. Louis, MO 63167